Allergan Sues Again To Block Generic Latisse

Law360, New York (August 18, 2011, 7:03 PM EDT) -- Allergan Inc. filed a patent infringement suit against Hi-Tech Pharmacal Co. Inc. in North Carolina on Wednesday in its latest effort to block a generic version of the eyelash growth treatment Latisse.

Allergan and Duke University claim that Hi-Tech's abbreviated new drug application infringes three patents in seeking permission to manufacture bimatoprost ophthalmic solution. The drug is marketed as Latisse, which was released in December 2008 as a treatment for hypotrichosis of the eyelashes and has become popular with consumers desiring longer or thicker lashes....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.